A clinical trial in the Fraser Valley is seeking additional participants to test whether or not the drug bamlanivimab can reduce hospitalizations and long-term side effects known as “Long COVID.”. The trial began in March, and needs another 100-150 participants who have tested positive for COVID-19 and have at least one co-morbidity. Bamlanivimab is one of two drugs, including antiviral remdesivir, to receive emergency Health Canada approval as a therapy to treat COVID-19. It is administered as an intravenous infusion for one hour in an outpatient clinic. The study underway is funded by a donation from manufacturer AbCellera.